Durable response to second-line m-FOLFIRINOX for advanced pancreatic adenocarcinoma in patients with performance status of two or less

被引：0
|
作者：
Das, A. [1 ]
Dean, A. [1 ]
Travers, N. [1 ]
Johansson, M. [1 ]
Yusoff, I. [1 ]
机构：
[1] St John God Subiaco, Bendat Canc Ctr, Subiaco, WA, Australia
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
182P
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Modified FOLFIRINOX as a second-line treatment in pancreatic adenocarcinoma patients with poor performance status.
    Das, Adarsh
    Dean, Andrew Peter
    Higgs, Domenic
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [2] Modified FOLFIRINOX as a second -line treatment in pancreatic adenocarcinoma following gemcitabine plus nab-paclitaxel failure in patients with performance status two or less
    Das, A.
    Dean, A.
    ANNALS OF ONCOLOGY, 2019, 30
  • [3] Gemcitabine as second-line chemotherapy after Folfirinox failure in advanced pancreatic adenocarcinoma: A retrospective study
    Viaud, Juliette
    Brac, Clemence
    Artru, Pascal
    Le Pabic, Estelle
    Leconte, Berengere
    Bodere, Anais
    Pracht, Marc
    Le Sourd, Samuel
    Edeline, Julien
    Lievre, Astrid
    DIGESTIVE AND LIVER DISEASE, 2017, 49 (06) : 692 - 696
  • [4] Modified FOLFIRINOX (mFOLFIRINOX) as second-line chemotherapy in pancreatic adenocarcinoma.
    Dean, Andrew Peter
    Higgs, Domenic
    James, Alex
    Van Gemert, Tegan
    James, Alena Talia
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [5] Role of second-line gemcitabine after FOLFIRINOX failure in advanced pancreatic adenocarcinoma: A retrospective analysis.
    Lino, Aline Da Rocha
    Martins Junior, Rodnei Merlrina
    Abrahao, Carina Mina
    Moreira, Raphael Brandao
    Soares de Sousa, Tarcia Tarciane
    Gomes, Jessica Ribeiro
    Alessandretti, Matheus Bongers
    Fernandes Amarante, Marcus Paulo
    Ferrian, Andrea Malta
    Barros Schutz, Fabio Augusto
    Kawamura, Carolina
    Schmerling, Rafael
    Cruz, Marcelo Rocha
    Peixoto, Renata D'Alpino
    Cesar Machado, Marcel Cerqueira
    Buzaid, Antonio C.
    Maluf, Fernando C.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [6] Use of gemcitabine as a second-line treatment following chemotherapy with folfirinox for metastatic pancreatic adenocarcinoma
    Sarabi, Matthieu
    Mais, Laetitia
    Oussaid, Nadia
    Desseigne, Francoise
    Guibert, Pierre
    De La Fouchardiere, Christelle
    ONCOLOGY LETTERS, 2017, 13 (06) : 4917 - 4924
  • [7] Second-Line Treatment for Advanced Pancreatic Adenocarcinoma: Is There a Role for Gemcitabine?
    Girardi, Daniel M.
    Faria, Luiza Dib B. B.
    Teixeira, Marcela C.
    Costa, Frederico P.
    Hoff, Paulo Marcelo G.
    Fernandes, Gustavo S.
    JOURNAL OF GASTROINTESTINAL CANCER, 2019, 50 (04) : 860 - 866
  • [8] Second-Line Treatment for Advanced Pancreatic Adenocarcinoma: Is There a Role for Gemcitabine?
    Daniel M. Girardi
    Luiza Dib B. B. Faria
    Marcela C. Teixeira
    Frederico P. Costa
    Paulo Marcelo G. Hoff
    Gustavo S. Fernandes
    Journal of Gastrointestinal Cancer, 2019, 50 : 860 - 866
  • [9] Modified GTX as second-line therapy for advanced pancreatic adenocarcinoma
    Ajouz H.
    Mukherji D.
    Haydar A.
    Yakan A.S.
    Saleh A.
    Elias E.
    Temraz S.
    Faraj W.
    Khalife M.
    Shamseddine A.
    Journal of Gastrointestinal Cancer, 2014, 45 (1) : 109 - 112
  • [10] Gemcitabine and nab-paclitaxel retreatment as a third-line therapy following second-line FOLFIRINOX for advanced pancreatic adenocarcinoma.
    Dean, Andrew Peter
    Das, Adarsh
    McNulty, Meabh
    Higgs, Domenic
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345